KR101662699B1 - 페녹시메틸 헤테로고리 화합물 - Google Patents
페녹시메틸 헤테로고리 화합물 Download PDFInfo
- Publication number
- KR101662699B1 KR101662699B1 KR1020117028223A KR20117028223A KR101662699B1 KR 101662699 B1 KR101662699 B1 KR 101662699B1 KR 1020117028223 A KR1020117028223 A KR 1020117028223A KR 20117028223 A KR20117028223 A KR 20117028223A KR 101662699 B1 KR101662699 B1 KR 101662699B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- imidazo
- alkyl
- methoxyphenyl
- pharmaceutically acceptable
- Prior art date
Links
- 0 *C1(*)OC(*)=CC1=O Chemical compound *C1(*)OC(*)=CC1=O 0.000 description 1
- ITKKFLCLPSSWOR-UHFFFAOYSA-N CC(C)(C1=O)OC(c(cc2)ccc2OC)=C1c(cc1)ccc1OCc1c(C)cc(C)cn1 Chemical compound CC(C)(C1=O)OC(c(cc2)ccc2OC)=C1c(cc1)ccc1OCc1c(C)cc(C)cn1 ITKKFLCLPSSWOR-UHFFFAOYSA-N 0.000 description 1
- GPFTVIIACHNMNI-UHFFFAOYSA-N CC(C)(C1=O)OC(c(cc2)ccc2OC)=C1c(cc1)ccc1OCc1c[n](cccc2)c2n1 Chemical compound CC(C)(C1=O)OC(c(cc2)ccc2OC)=C1c(cc1)ccc1OCc1c[n](cccc2)c2n1 GPFTVIIACHNMNI-UHFFFAOYSA-N 0.000 description 1
- AQQONKYJYUDLRR-UHFFFAOYSA-N CC(C)(C1=O)OC(c(cc2)ccc2OC)=C1c(cc1)ccc1OCc1c[n]2c(C)cccc2n1 Chemical compound CC(C)(C1=O)OC(c(cc2)ccc2OC)=C1c(cc1)ccc1OCc1c[n]2c(C)cccc2n1 AQQONKYJYUDLRR-UHFFFAOYSA-N 0.000 description 1
- LBCREEUWXFNSAC-UHFFFAOYSA-N ClCc1c[n](cccc2)c2n1 Chemical compound ClCc1c[n](cccc2)c2n1 LBCREEUWXFNSAC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17641309P | 2009-05-07 | 2009-05-07 | |
US61/176,413 | 2009-05-07 | ||
PCT/US2009/068644 WO2010128995A1 (en) | 2009-05-07 | 2009-12-18 | Phenoxymethyl heterocyclic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120027268A KR20120027268A (ko) | 2012-03-21 |
KR101662699B1 true KR101662699B1 (ko) | 2016-10-05 |
Family
ID=41549054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117028223A KR101662699B1 (ko) | 2009-05-07 | 2009-12-18 | 페녹시메틸 헤테로고리 화합물 |
Country Status (33)
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2297133B1 (en) | 2008-06-25 | 2017-09-13 | Forum Pharmaceuticals Inc. | 1, 2 disubstituted heterocyclic compounds |
WO2010128995A1 (en) | 2009-05-07 | 2010-11-11 | Envivo Pharmaceuticals, Inc. | Phenoxymethyl heterocyclic compounds |
CN103476757A (zh) | 2011-02-18 | 2013-12-25 | 阿勒根公司 | 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物 |
EP2858982A4 (en) | 2012-06-12 | 2015-11-11 | Abbvie Inc | PYRIDINONE AND PYRIDAZINONE DERIVATIVES |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
ES2480341B1 (es) | 2013-01-24 | 2015-01-22 | Palobiofarma S.L | Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10) |
TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
TWI634114B (zh) * | 2013-05-08 | 2018-09-01 | 永恒生物科技公司 | 作為激酶抑制劑之呋喃酮化合物 |
US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007077490A2 (en) | 2006-01-05 | 2007-07-12 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003513092A (ja) * | 1999-11-05 | 2003-04-08 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) | 新規複素環化合物及びその医薬としての使用 |
US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
AU2003244080A1 (en) | 2002-06-26 | 2004-01-19 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
RS51385B (en) | 2005-01-07 | 2011-02-28 | Pfizer Products Inc. | HETEROAROMATIC COMPOUNDS OF HINOLINE AND THEIR USE AS PDE10 INHIBITORS |
EP1845098A1 (en) * | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
US20090176829A1 (en) * | 2006-05-02 | 2009-07-09 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
WO2008033455A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors |
FR2928924B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
EP2297133B1 (en) * | 2008-06-25 | 2017-09-13 | Forum Pharmaceuticals Inc. | 1, 2 disubstituted heterocyclic compounds |
WO2010128995A1 (en) | 2009-05-07 | 2010-11-11 | Envivo Pharmaceuticals, Inc. | Phenoxymethyl heterocyclic compounds |
MX2012002591A (es) * | 2009-09-03 | 2012-04-02 | Allergan Inc | Compuestos como moduladores de tirosina cinasas. |
PL2605652T3 (pl) * | 2010-08-18 | 2018-04-30 | Samumed, Llc | Diketony i hydroksyketony jako aktywatory szlaku sygnalizacji kateninowej |
-
2009
- 2009-12-18 WO PCT/US2009/068644 patent/WO2010128995A1/en active Application Filing
- 2009-12-18 SG SG2011081437A patent/SG175900A1/en unknown
- 2009-12-18 MY MYPI2011005358A patent/MY183910A/en unknown
- 2009-12-18 PT PT131503229T patent/PT2617420E/pt unknown
- 2009-12-18 CN CN200980159735.6A patent/CN102459242B/zh not_active Expired - Fee Related
- 2009-12-18 BR BRPI0924617A patent/BRPI0924617A8/pt not_active IP Right Cessation
- 2009-12-18 PL PL09796217T patent/PL2427454T3/pl unknown
- 2009-12-18 PE PE2011001918A patent/PE20120900A1/es not_active Application Discontinuation
- 2009-12-18 MX MX2011011755A patent/MX2011011755A/es active IP Right Grant
- 2009-12-18 CA CA2761032A patent/CA2761032A1/en not_active Abandoned
- 2009-12-18 KR KR1020117028223A patent/KR101662699B1/ko active IP Right Grant
- 2009-12-18 DK DK13150322.9T patent/DK2617420T3/da active
- 2009-12-18 RS RS20150803A patent/RS54529B1/en unknown
- 2009-12-18 DK DK09796217.9T patent/DK2427454T3/da active
- 2009-12-18 HU HUE13150322A patent/HUE026238T2/en unknown
- 2009-12-18 PL PL13150322T patent/PL2617420T3/pl unknown
- 2009-12-18 EP EP09796217A patent/EP2427454B1/en active Active
- 2009-12-18 PT PT97962179T patent/PT2427454E/pt unknown
- 2009-12-18 RS RS20130218A patent/RS52838B/en unknown
- 2009-12-18 ES ES09796217T patent/ES2409404T3/es active Active
- 2009-12-18 US US12/642,026 patent/US8343973B2/en not_active Expired - Fee Related
- 2009-12-18 SI SI200930609T patent/SI2427454T1/sl unknown
- 2009-12-18 AU AU2009345802A patent/AU2009345802B2/en not_active Ceased
- 2009-12-18 RU RU2011149637/04A patent/RU2531274C2/ru not_active IP Right Cessation
- 2009-12-18 EP EP13150322.9A patent/EP2617420B1/en active Active
- 2009-12-18 SI SI200931314T patent/SI2617420T1/sl unknown
- 2009-12-18 EP EP15184753.0A patent/EP3020716A1/en not_active Withdrawn
- 2009-12-18 ME MEP-2015-210A patent/ME02375B/me unknown
- 2009-12-18 JP JP2012509778A patent/JP5628902B2/ja not_active Expired - Fee Related
- 2009-12-18 CN CN201510438849.1A patent/CN105125547A/zh active Pending
- 2009-12-18 NZ NZ596753A patent/NZ596753A/xx not_active IP Right Cessation
- 2009-12-18 ES ES13150322.9T patent/ES2554788T3/es active Active
-
2011
- 2011-11-03 IL IL216149A patent/IL216149A/en not_active IP Right Cessation
- 2011-11-07 CL CL2011002792A patent/CL2011002792A1/es unknown
- 2011-11-11 CO CO11153626A patent/CO6460744A2/es active IP Right Grant
- 2011-11-24 EC EC2011011479A patent/ECSP11011479A/es unknown
- 2011-12-05 CR CR20110648A patent/CR20110648A/es unknown
- 2011-12-05 ZA ZA2011/08920A patent/ZA201108920B/en unknown
-
2012
- 2012-08-21 HK HK12108181.8A patent/HK1167402A1/xx not_active IP Right Cessation
- 2012-12-20 US US13/722,595 patent/US8946222B2/en not_active Expired - Fee Related
-
2013
- 2013-05-31 HR HRP20130482AT patent/HRP20130482T1/hr unknown
- 2013-06-20 PH PH12013501321A patent/PH12013501321A1/en unknown
- 2013-06-20 SM SM201300070T patent/SMT201300070B/xx unknown
-
2014
- 2014-01-06 HK HK14100085.0A patent/HK1186981A1/xx not_active IP Right Cessation
- 2014-10-02 JP JP2014204220A patent/JP5943053B2/ja not_active Expired - Fee Related
- 2014-12-09 US US14/564,507 patent/US20150322069A1/en not_active Abandoned
-
2015
- 2015-11-25 HR HRP20151273TT patent/HRP20151273T1/hr unknown
-
2016
- 2016-02-04 SM SM201600031T patent/SMT201600031B/it unknown
- 2016-02-10 IL IL244059A patent/IL244059A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007077490A2 (en) | 2006-01-05 | 2007-07-12 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101662699B1 (ko) | 페녹시메틸 헤테로고리 화합물 | |
EP2297133B1 (en) | 1, 2 disubstituted heterocyclic compounds | |
KR20110025984A (ko) | 포스포디에스테라제 10 억제제로서의 이치환된 페닐 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |